3 High-Risk Biotechs That Could Pop or Drop in 2018 Post author:Sam Post published:February 4, 2018 Post category:BioPharma A look at three biotech companies that face make-or-break catalysts this year. Source: BioSpace You Might Also Like Takeda Axes Sales Jobs, Forces Hundreds of Employees to Relocate to Boston July 17, 2017 Filings Reveal Concert Pharma Spurned $250 Million Buyout Offer From Vertex in November 2016 March 26, 2017 HEALTHSOUTH Reports Strong Revenue And Earnings Growth For Fourth Quarter 2016 And Reiterates Full-Year 2017 Guidance February 21, 2017
Filings Reveal Concert Pharma Spurned $250 Million Buyout Offer From Vertex in November 2016 March 26, 2017
HEALTHSOUTH Reports Strong Revenue And Earnings Growth For Fourth Quarter 2016 And Reiterates Full-Year 2017 Guidance February 21, 2017
